IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of...
IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1‐mutated AML after allogeneic hematopoietic cell transplantation
About this item
Full title
Author / Creator
Caillet, Adrien , Simonet‐Boissard, Marion , Forcade, Edouard , Robin, Marie , Rubio, Marie‐Thérèse , Couturier, Marie‐Anne , Srour, Micha , Maillard, Natacha , Devillier, Raynier , Huynh, Anne , Bourhis, Jean‐Henri , Simand, Célestine , Chantepie, Sylvain , Boisson, Cyril , Kroemer, Marie , Deconinck, Eric and Berceanu, Ana
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Relapse is the leading cause of transplant failure, and the prognosis of these patients is poor with a 2-year survival rate of less than 20%, especially in patients with early relapse after alloHCT (within 6 months). In a randomized trial evaluating ivosidenib in combination with azacitidine in newly diagnosed AML ineligible for intensive chemother...
Alternative Titles
Full title
IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1‐mutated AML after allogeneic hematopoietic cell transplantation
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_89e8042239f5469e8a10678c118f073d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_89e8042239f5469e8a10678c118f073d
Other Identifiers
ISSN
2572-9241
E-ISSN
2572-9241
DOI
10.1002/hem3.44
